DAVID LEE JOHNSON - 01 Oct 2021 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role: Chief Commercial Officer
Signature: /s/ Miguel Carrillo, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Oct 2021
Net transactions value: -$56,962
Form type: 4
Filing time: 05 Oct 2021, 16:05:21 UTC
Previous filing: 03 Sep 2021
Next filing: 03 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GBT	Common Stock	Options Exercise		+4,375	+12%		41,242	01 Oct 2021	Direct	F1
transaction	GBT	Common Stock	Tax liability	$56,962	-2,170	-5.3%	$26.25	39,072	01 Oct 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GBT	Restricted Stock Units	Options Exercise	$0	-4,375	-50%	$0.000000	4,375	01 Oct 2021	Common Stock	4,375		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2	Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs.
F3	The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.